Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease

• Main Authors: Abdulmajeed, J. (Author), Al Khal, A. (Author), Albayat, S.S.A (Author), Al-Kuwari, M.G (Author), Al-Romaihi, H.E (Author), Al-Shamali, M.H.M.A (Author), Al-Thani, M.H (Author), Baaboura, R. (Author), Bansal, D. (Author), Bertollini, R. (Author), Chivese, T. (Author), Cyprian, F.S (Author), Doi, S.A.R (Author), Farag, E. (Author), Himatt, S.M (Author), Kaleeckal, A.H (Author), Kandy, M.C (Author), Khogali, H.S (Author), Latif, A.N (Author), Mundodan, J.M.A (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: case-control; conditional effectiveness; COVID-19; mRNA vaccine; vaccine effectiveness; waning
• Online Access: View Fulltext in Publisher
• ISBN: 2076393X (ISSN)
• DOI: 10.3390/vaccines10071036

Waning immunity following administration of mRNA-based COVID-19 vaccines remains a concern for many health systems. We undertook a study to determine if recent reports of waning for severe disease could have been attributed to design-related bias by conducting a study only among those detected with a first SARS-CoV-2 infection. We used a matched case-control study design with the study base being all individuals with first infection with SARS-CoV-2 reported in the State of Qatar between 1 January 2021 and 20 February 2022. Cases were those detected with first SARS-CoV-2 infection requiring intensive care (hard outcome), while controls were those detected with first SARS-CoV-2 infection who recovered without the need for intensive care. Cases and controls were matched in a 1:30 ratio for the calendar month of infection and the comorbidity category. Duration and magnitude of conditional vaccine effectiveness against requiring intensive care and the number needed to vaccinate (NNV) to prevent one more case of COVID-19 requiring intensive care was estimated for the mRNA (BNT162b2/mRNA-1273) vaccines. Conditional vaccine effectiveness against requiring intensive care was 59% (95% confidence interval (CI), 50 to 76) between the first and second dose, and strengthened to 89% (95% CI, 85 to 92) between the second dose and 4 months post the second dose in persons who received a primary course of the vaccine. There was no waning of vaccine effectiveness in the period from 4 to 6, 6 to 9, and 9 to 12 months after the second dose. This study demonstrates that, contrary to mainstream reports using hierar-chical measures of effectiveness, conditional vaccine effectiveness against requiring intensive care remains robust till at least 12 months after the second dose of mRNA-based vaccines. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.